Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications.
about
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Drugs acting on homeostasis: challenging cancer cell adaptation.Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines.Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens.The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.
P2860
Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mechanistic studies on the syn ...... and its clinical implications.
@en
Mechanistic studies on the syn ...... and its clinical implications.
@nl
type
label
Mechanistic studies on the syn ...... and its clinical implications.
@en
Mechanistic studies on the syn ...... and its clinical implications.
@nl
prefLabel
Mechanistic studies on the syn ...... and its clinical implications.
@en
Mechanistic studies on the syn ...... and its clinical implications.
@nl
P2093
P2860
P1476
Mechanistic studies on the syn ...... and its clinical implications.
@en
P2093
Benigno C Valdez
Borje S Andersson
David Murray
Donna M Weber
Francesco Turturro
Guiyun Wang
Jatin Shah
Michael Wang
Muzaffar H Qazilbash
Richard E Champlin
P2860
P304
P356
10.1016/J.EXPHEM.2013.04.009
P577
2013-05-03T00:00:00Z